Namely, it is important to prioritise protein, vitamins, minerals, and hydration to support the overall health during therapy, up until weight stabilises
Eur J Immunol 46(1):223229
The broader 2026 context matters: as of May 2026, the FDA has proposed regulatory changes affecting compounded semaglutide and tirzepatide, with a public comment period closing June 29, 2026
Probably not all of it, but some regain is common
That flexibility makes it the default choice for most protocols
Originally developed for type 2 diabetes, Semaglutide (known by brand names Ozempic and Wegovy) has shown remarkable efficacy for weight management -- with clinical trials demonstrating average weight loss of 15-20% of body weight